A new approach to an old problem: Synthetic biology tools for human disease and metabolism

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 76, Issue , 2011, Pages 145-154

  Burrill, D R ^a   Boyle, P M ^a   Silver, P A ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; CARBON; CHIMERIC PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUCOSE; PEGINTERFERON ALPHA2A; RECOMBINANT DNA;

ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; BRAIN METABOLISM; DISEASES; GENE DELETION; GLUCOSE BLOOD LEVEL; INTRACELLULAR SIGNALING; LIGAND BINDING; MAMMAL; METABOLIC DISORDER; METABOLIC ENGINEERING; METABOLIC REGULATION; METABOLISM; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; RIBOSWITCH; RNA INTERFERENCE; SYNTHETIC BIOLOGY; TRANSCRIPTION REGULATION; TRANSLATION REGULATION; GENE THERAPY; HUMAN; MEDICAL DEVICE; MOLECULAR GENETICS; SIGNAL TRANSDUCTION;

DISEASE; GENE EXPRESSION REGULATION; HUMANS; METABOLIC ENGINEERING; METABOLISM; SIGNAL TRANSDUCTION; SYNTHETIC BIOLOGY;

EID: 84867420739     PISSN: 00917451     EISSN: None     Source Type: Book Series    
DOI: 10.1101/sqb.2011.76.010686     Document Type: Article

References (78)

1. Agapakis CM, Niederholtmeyer H, Noche RR, Lieberman TD, Megason SG, Way JC, Silver PA. 2011. Towards a synthetic chloroplast. PLoS ONE 6: e18877.
2. Ajo-Franklin CM, Drubin DA, Eskin JA, Gee EPS, Landgraf D, Phillips I, Silver PA. 2007. Rational design of memory in eukaryotic cells. Genes Dev 21: 2271-2276.
3. Anderson JC, Clarke EJ, Arkin AP, Voigt CA. 2006. Environmentally controlled invasion of cancer cells by engineered bacteria. J Mol Biol 355: 619-627.
4. Anderson JC, Voigt CA, Arkin AP. 2007. Environmental signal integration by a modular AND gate. Mol Syst Biol 3: 133.
5. Ausländer S, Wieland M, Fussenegger M. 2011. Smart medication through combination of synthetic biology and cell microencapsulation. Metab Eng doi: 10.1016/j.ymben.2011.06.003.
6. Bara H, Sambanis A. 2008. Insulin-secreting L-cells for the treatment of insulin-dependent diabetes. Biochem Biophys Res Commun 371: 39-43.
7. Bayer TS, Smolke CD. 2005. Programmable ligand-controlled riboregulators of eukaryotic gene expression. Nat Biotechnol 23: 337-343.
8. Beisel CL, Bayer TS, Hoff KG, Smolke CD. 2008. Modelguided design of ligand-regulated RNAi for programmable control of gene expression. Mol Syst Biol 4: 224.
9. Beltran A, Parikh S, Liu Y, Cuevas BD, Johnson GL, Futscher BW, Blancafort P. 2007. Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene 26: 2791-2798.
10. Berk AJ. 2005. Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 24: 7673-7685.
11. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, et al. 2010. The landscape of somatic copy-number alteration across human cancers. Nature 463: 899-905.
12. Boyle PM, Silver PA. 2009. Harnessing nature's toolbox: Regulatory elements for synthetic biology. J R Soc Interface 6 (Suppl 4): S535-S546.
13. Braselmann S, Graninger P, Busslinger M. 1993. A selective transcriptional induction system for mammalian cells based on Gal4-estrogen receptor fusion proteins. Proc Natl Acad Sci 90: 1657-1661.
14. Bro C, Regenberg B, Förster J, Nielsen J. 2006. In silico aided metabolic engineering of Saccharomyces cerevisiae for improved bioethanol production. Metab Eng 8: 102-111.
15. Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE. 2005. Mitochondrial abnormalities in Alzheimer brain: Mechanistic implications. Ann Neurol 57: 695-703.
16. Burgard AP, Pharkya P, Maranas CD. 2003. Optknock: A bilevel programming framework for identifying gene knockout strategies for microbial strain optimization. Biotechnol Bioeng 84: 647-657.
17. Burrill DR, Silver PA. 2010. Making cellular memories. Cell 140: 13-18.
18. Burrill DR, Silver PA. 2011. Synthetic circuit identifies subpopulations with sustained memory of DNA damage. Genes Dev 25: 434-439.
19. Cironi P, Swinburne IA, Silver PA. 2008. Enhancement of cell type specificity by quantitative modulation of a chimeric ligand. J Biol Chem 283: 8469-8476.
20. Culler SJ, Hoff KG, Smolke CD. 2010. Reprogramming cellular behavior with RNA controllers responsive to endogenous proteins. Science 330: 1251-1255.
21. Dean JT, Tran L, Beaven S, Tontonoz P, Reue K, Dipple KM, Liao JC. 2009. Resistance to diet-induced obesity in mice with synthetic glyoxylate shunt. Cell Metab 9: 525-536.
22. Deans TL, Cantor CR, Collins JJ. 2007. A tunable genetic switch based on RNAi and repressor proteins for regulating gene expression in mammalian cells. Cell 130: 363-372.
23. Dekel E, Alon U. 2005. Optimality and evolutionary tuning of the expression level of a protein. Nature 436: 588-592.
24. Denèfle PP. 2011. Introduction to gene therapy: A clinical aftermath. Meth Mol Biol 737: 27-44.
25. Duan F, March JC. 2010. Engineered bacterial communication prevents Vibrio cholerae virulence in an infant mouse model. Proc Natl Acad Sci 107: 11260-11264.
26. Duan F, Curtis KL, March JC. 2008. Secretion of insulinotropic proteins by commensal bacteria: Rewiring the gut to treat diabetes. Appl Environ Microbiol 74: 7437-7438.
27. Duarte NC, Herrga°rd MJ, Palsson BO. 2004. Reconstruction and validation of Saccharomyces cerevisiae iND750, a fully compartmentalized genome-scale metabolic model. Genome Res 14: 1298-1309.
28. Duarte NC, Becker SA, Jamshidi N, Thiele I, Mo ML, Vo TD, Srivas R, Palsson BO. 2007. Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc Natl Acad Sci 104: 1777-1782.
29. Edwards JS, Covert M, Palsson B. 2002. Metabolic modelling of microbes: The flux-balance approach. Environ Microbiol 4: 133-140.
30. Feist AM, Palsson BO. 2010. The biomass objective function. Curr Opin Microbiol 13: 344-349.
31. Fell D. 1997. Understanding the Control of Metabolism, chapters 4 and 5. Portland Press, London.
32. Friedland AE, Lu TK, Wang X, Shi D, Church G, Collins JJ. 2009. Synthetic gene networks that count. Science 324: 1199-1202.
33. Gabardi S, Halloran PF, Friedewald J. 2011. Managing risk in developing transplant immunosuppressive agents: The new regulatory environment. Am J Transplant 11: 1803-1809.
34. Gianchandani EP, Chavali AK, Papin JA. 2010. The application of flux balance analysis in systems biology. Wiley Interdiscip Rev Syst Biol Med 2: 372-382.
35. Greber D, El-Baba MD, Fussenegger M. 2008. Intronically encoded siRNAs improve dynamic range of mammalian gene regulation systems and toggle switch. Nucl Acids Res 36: e101.
36. Hansen KH, Bracken AP, Pasini D, Dietrich N, Gehani SS, Monrad A, Rappsilber J, Lerdrup M, Helin K. 2008. A model for transmission of the H3K27me3 epigenetic mark. Nature 10: 1291-1300.
37. Haynes KA, Silver PA. 2009. Eukaryotic systems broaden the scope of synthetic biology. J Cell Biol 187: 589-596.
38. Haynes KA, Silver PA. 2011. Synthetic reversal of epigenetic silencing. J Biol Chem 286: 27176-27182.
39. He P, Zhu D, Hu J-J, Peng J, Chen L-S, Lu G-X. 2010. pcDNA3.1(2)-mediated ribozyme targeting of HER-2 suppresses breast cancer tumor growth. Mol Biol Rep 37: 1597-1604.
40. Ibarra RU, Edwards JS, Palsson BO. 2002. Escherichia coli K-12 undergoes adaptive evolution to achieve in silico predicted optimal growth. Nature 420: 186-189.
41. Jerby L, Shlomi T, Ruppin E. 2010. Computational reconstruction of tissue-specific metabolic models: Application to human liver metabolism. Mol Syst Biol 6: 401.
42. Kennedy CJ, Boyle PM, Waks Z, Silver PA. 2009. Systems-level engineering of nonfermentative metabolism in yeast. Genetics 183: 385-397.
43. Khalil AS, Collins JJ. 2010. Synthetic biology: Applications come of age. Nat Rev Genet 11: 367-379.
44. Lagenaur LA, Sanders-Beer BE, Brichacek B, Pal R, Liu X, Liu Y, Yu R, Venzon D, Lee PP, Hamer DH. 2011. Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Mucosal Immunol 4: 648-657.
45. Le Blanc K, Ringdèn O. 2007. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 262: 509-525.
46. Lewis NE, Schramm G, Bordbar A, Schellenberger J, Andersen MP, Cheng JK, Patel N, Yee A, Lewis RA, Eils R, et al. 2010. Large-scale in silico modeling of metabolic interactions between cell types in the human brain. Nat Biotechnol 28: 1279-1285.
47. Li X, Li C, Shang D, Li J, Han J, Miao Y, Wang Y, Wang Q, Li W, Wu C, et al. 2011. The implications of relationships between human diseases and metabolic subpathways. PLoS ONE 6: e21131.
48. Liu X, Lagenaur LA, Simpson DA, Essenmacher KP, Frazier-Parker CL, Liu Y, Tsai D, Rao SS, Hamer DH, Parks TP, et al. 2006. Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrob Agents Chemother 50: 3250-3259.
49. Marshall E. 1999. Clinical Trials: Gene therapy death prompts review of adenovirus vector. Science 286: 2244-2245.
50. Martins Dos Santos V, Müller M, de Vos WM. 2010. Systems biology of the gut: The interplay of food, microbiota and host at the mucosal interface. Curr Opin Biotechnol 21: 539-550.
51. Meijsing SH, Pufall MA, So AY, Bates DL, Chen L, Yamamoto KR. 2009. DNA binding site sequence directs glucocorticoid receptor structure and activity. Science 324: 407-410.
52. Moreno-Sànchez R, Saavedra E, Rodrìguez-Enrìquez S, Gallardo-Pèrez JC, Quezada H, Westerhoff HV. 2010. Metabolic control analysis indicates a change of strategy in the treatment of cancer. Mitochondrion 10: 626-639.
53. Mulhbacher J, Brouillette E, Allard M, Fortier L-C, Malouin F, Lafontaine DA. 2010. Novel riboswitch ligand analogs as selective inhibitors of guanine-related metabolic pathways. PLoS Pathog 6: e1000865.
54. Newgard CB. 1992. Cellular engineering for the treatment of metabolic disorders: Prospects for therapy in diabetes. Biotechnology (NY) 10: 1112-1120.
55. Oberhardt MA, Palsson BO, Papin JA. 2009. Applications of genome-scale metabolic reconstructions. Mol Syst Biol 5: 320.
56. Ohno K, Ishihata K, Tanaka-Azuma Y, Yamada T. 2008. A genotoxicity test system based on p53R2 gene expression in human cells: Assessment of its reactivity to various classes of genotoxic chemicals. Mutat Res 656: 27-35.
57. Palmer R. 2011. Fecal matters. Nat Med 17: 150-152.
58. Pharkya P, Burgard AP, Maranas CD. 2004. OptStrain: A computational framework for redesign of microbial production systems. Genome Res 14: 2367-2376.
59. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, et al. 2010. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464: 59-65.
60. Rao S, Hu S, McHugh L, Lueders K, Henry K, Zhao Q, Fekete RA, Kar S, Adhya S, Hamer DH. 2005. Toward a live microbial microbicide for HIV: Commensal bacteria secreting an HIV fusion inhibitor peptide. Proc Natl Acad Sci 102: 11993-11998.
61. Rasnick D, Duesberg PH. 1999. How aneuploidy affects metabolic control and causes cancer. Biochem J 340 (Pt 3): 621-630.
62. Rinaudo K, Bleris L, Maddamsetti R, Subramanian S, Weiss R, Benenson Y. 2007. A universal RNAi-based logic evaluator that operates in mammalian cells. Nat Biotechnol 25: 795-801.
63. Rocha I, Maia P, Evangelista P, Vilaca P, Soares S, Pinto JP, Nielsen J, Patil KR, Ferreira EC, Rocha M. 2010. OptFlux: An open-source software platform for in silico metabolic engineering. BMC Syst Biol 4: 45.
64. Schrattenholz A, Groebe K, Soskic V. 2010. Systems biology approaches and tools for analysis of interactomes and multitarget drugs. Meth Mol Biol 662: 29-58.
65. Segrè D, Vitkup D, Church GM. 2002. Analysis of optimality in natural and perturbed metabolic networks. Proc Natl Acad Sci 99: 15112-15117.
66. Shlomi T, Cabili MN, Herrga°rd MJ, Palsson BO, Ruppin E. 2008. Network-based prediction of human tissue-specific metabolism. Nat Biotechnol 26: 1003-1010.
67. Smolke CD, Win MN. 2010. Regulating gene expression through engineered RNA technologies. In The metabolic pathway engineering hand book. CRC Press, San Diego.
68. Stolyar S, Van Dien S, Hillesland KL, Pinel N, Lie TJ, Leigh JA, Stahl DA. 2007. Metabolic modeling of a mutualistic microbial community. Mol Syst Biol 3: 92.
69. Strähle U, Klock G, Schütz G. 1987. A DNA sequence of 15 base pairs is sufficient to mediate both glucocorticoid and progesterone induction of gene expression. Proc Natl Acad Sci 84: 7871-7875.
70. Suhre K, Shin S-Y, Petersen A-K, Mohney RP, Meredith D, Wägele B, Altmaier E, CARDIoGRAM, Deloukas P, Erdmann J, et al. 2011. Human metabolic individuality in biomedical and pharmaceutical research. Nature 477: 54-60.
71. Suzuki A, Nakauchi H, Taniguchi H. 2003. Glucagon-like peptide 1 (1-37) converts intestinal epithelial cells into insulinproducing cells. Proc Natl Acad Sci 100: 5034-5039.
72. Swinburne IA, Miguez DG, Landgraf D, Silver PA. 2008. Intron length increases oscillatory periods of gene expression in animal cells. Genes Dev 22: 2342-2346.
73. Tang YL, Tang Y, Zhang YC, Agarwal A, Kasahara H, Qian K, Shen L, Phillips MI. 2005. A hypoxia-inducible vigilant vector system for activating therapeutic genes in ischemia. Gene Ther 12: 1163-1170.
74. Terzer M, Maynard ND, Covert MW, Stelling J. 2009. Genome-scale metabolic networks. Wiley Interdiscip Rev Syst Biol Med 1: 285-297.
75. Thomas S, Fell DA. 1996. Design of metabolic control for large flux changes. J Theor Biol 182: 285-298.
76. TiggesM, Marquez-Lago TT, Stelling J, Fussenegger M. 2009. A tunable synthetic mammalian oscillator. Nature 457: 309-312.
77. Tilg H, Kaser A. 2011. Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest 121: 2126-2132.
78. Trounson A, Thakar RG, Lomax G, Gibbons D. 2011. Clinical trials for stem cell therapies. BMC Med 9: 52.